News & Events
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (opens in a new tab)
– Preclinical data suggest efficacy of new investigational microbial consortium, called DE486, to reduce chemotherapy-induced mucositis inflammation – – A Phase 1b clinical trial to assess whether SER-155 prevents life-threatening complications of stem cell transplant – CAMBRIDGE, Mass.…
Microba appoints CRO for IBD Clinical Trial (opens in a new tab)
Microba has appointed Beyond Drug Development as the lead Contract Research Organisation (CRO) for its upcoming Phase 1 trial of novel microbial cell therapy, MAP 315. The post Microba appoints CRO for IBD Clinical Trial appeared first on Microba Life Sciences.…
Microba signs partnership with nib-backed Midnight Health (opens in a new tab)
Microba has signed a strategic partnership agreement with nib Holdings Limited backed digital healthcare company Midnight Health, to deliver a personalised health service to the Australian consumer market. The post Microba signs partnership with nib-backed Midnight Health appeared first on Microba Life Sciences.…
Microbiome and Bile Acid Restoration was Consistent Across Three Clinical Trials of Rbx2660 for Recurrent Clostridioides Difficile Infection: A Combined Analysis (opens in a new tab)
Colleen Kraft MD1, Sahil Khanna MBBS2, Maha Assi MS MPH3, Paul Feuerstadt MD4, Adam Harvey PhD5, Lindy Bancke PharmD51Emory University, Atlanta, GA, USA; 2Mayo Ken Blount PhD1, Heidi Hau PhD1, Romeo Papazyan PhD2, Bryan Fuchs PhD2, Bill Shannon PhD MBA3, Carlos Gonzalez MS31Rebiotix Inc, Roseville, MN, USA, A Ferring C…
Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting (opens in a new tab)
Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in which VE303 was well tolerated and highly active at preventing Clostridioides difficile infection recurrence in subjects at high risk of recurrence Further CONSORTIUM study analysis shows that the VE303 high dose led to more robust colonization…
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting (opens in a new tab)
– In ECOSPOR lll, Seres’ lead therapeutic candidate incorporated itself rapidly and durably into the microbiome to prevent C. difficile infection recurrence – – Within one week of treatment, SER-109 was observed to diversify the microbiome and support the production of fatty acids that inhibit the…
Genetic Analysis AS and Omnigene Medical Technologies Ltd. enter a distribution agreement to launch GA-map® in the United Arabic Emirates (UAE) market (opens in a new tab)
The post Genetic Analysis AS and Omnigene Medical Technologies Ltd. enter a distribution agreement to launch GA-map® in the United Arabic Emirates (UAE) market appeared first on Genetic Analysis.…
Interim report January – March 2022 (opens in a new tab)
The post Interim report January – March 2022 appeared first on Genetic Analysis.…
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting (opens in a new tab)
– Data underscore the ability of Seres’ lead therapeutic candidate to repair the microbiome – CAMBRIDGE, Mass. –(BUSINESS WIRE)–May 10, 2022– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial…
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates (opens in a new tab)
– SER-109 open label study results, including safety and efficacy data, including in over 260 individuals enrolled with recurrent C. difficile infection , anticipated in Q2 2022 – – FDA agreement obtained for rolling SER-109 Biologics License Application (BLA) plan; filing completion on track for…
Microbiota and Microbiota Restoration for Recurrent C. diff Infections (opens in a new tab)
Ken Blount, PhD, CSO Rebiotix Inc., A Ferring Company Summary Every person carries an extensive and diverse community of microbes that influence daily health The community of healthy human bacterial microbiota can be disrupted by antibiotics, leading to C. diff infections and recurrent C. diff infections Investigationa…
Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Apr. 28, 2022– Seres Therapeutics, Inc . (NASDAQ: MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 4, 2022 at 8:30 a.m. ET to discuss first quarter 2022 results and provide…
Publication of Genetic Analysis’ 2021 Annual Report (opens in a new tab)
The post Publication of Genetic Analysis’ 2021 Annual Report appeared first on Genetic Analysis.…
Microba CSO presents to US industry conference (opens in a new tab)
Microba Chief Scientific Officer A/Professor Lutz Krause recently presented to microbiome research and development professionals at the 7th Annual Translational Microbiome Conference. The post Microba CSO presents to US industry conference appeared first on Microba Life Sciences.…
Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results (opens in a new tab)
Full Phase 1 data analysis of VE303, a defined bacterial consortium candidate for C. difficile infection, published in Cell Host & Microbe Positive topline Phase 2 results for VE303 announced in 2021; Phase 3 preparations underway Acceptance of three abstracts for podium presentations at Digestive Disease Week 2022 CAM…
Microba Life Sciences and Ginkgo Bioworks announce partnership to discover novel live biotherapeutics (opens in a new tab)
Partnership will leverage Ginkgo’s high throughput screening capabilities to identify potential therapeutic candidates for autoimmune diseases in Microba’s extensive strain bank. The post Microba Life Sciences and Ginkgo Bioworks announce partnership to discover novel live biotherapeutics appeared first on Microba Life…
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting (opens in a new tab)
– Preclinical data demonstrate SER-155 reduces infection and Graft-versus-Host Disease – CAMBRIDGE, Mass. –(BUSINESS WIRE)–Mar. 18, 2022– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow…
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial (opens in a new tab)
Robert Orenstein, Erik R. Dubberke, Sahil Khanna, Christine H. Lee, David Yoho, Stuart Johnson, Gail Hecht, Herbert L. DuPont, Dale N. Gerding, Ken F. Blount, Sarah Mische and Adam Harvey Background Effective treatment options for recurrent Clostridioides difficile infection (rCDI) are limited, with high recurrence rat…
Seres Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Mar. 10, 2022– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff , President and Chief Executive Officer of Seres Therapeutics , will present at the 32 nd Annual Oppenheimer Healthcare Conference…
Genetic Analysis strengthens its management team by hiring a Head of Operations (opens in a new tab)
The post Genetic Analysis strengthens its management team by hiring a Head of Operations appeared first on Genetic Analysis.…